Contera Pharma announces that CP0014753, a novel antisense oligonucleotide developed for the treatment of Canavan disease, is ready for IND-enabling studies

Posted on

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the preclinical candidate nomination of CP0014753, a highly potent and selective first-in-class antisense oligonucleotide directed to modulate expression of one of the genes involved in development of Canavan disease. The therapeutic concept behind CP-102 aims to reverse toxic accumulation of […]

Contera Pharma Welcomes New Board Members to Drive Strategic Growth

Posted on

[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to announce the appointment of new members to its Board of Directors. These strategic additions reflect Contera Pharma’s commitment to advancing innovative patient-centered therapies. Dr. Mahmoud Mahmoudian, FRS Dr. Mahmoud Mahmoudian brings over 25 […]

Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease

Posted on

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in a Phase 1b pharmacoscintigraphic study evaluating CP-012. This novel delayed-release, dual-pulse levodopa/carbidopa tablet is designed to address the distinct challenges of nocturnal immobility and early morning akinesia in Parkinson’s disease (PD) patients. These […]

Contera Pharma announces management changes to secure progression of lead programs and further expansion of pipeline

Posted on

[Hørsholm, September 6, 2024] – Contera Pharma A/S, a clinical-stage biotech company developing innovative therapies to treat neurological disorders, is pleased to announce key changes to its leadership team. These strategic appointments underscore the company’s commitment to advancing clinical excellence, financial integrity, and scientific innovation. Contera Pharma has welcomed Dr. Anne Birk Østerskov as Chief […]